LTAS
SGMO

Linden Thomas Advisory Services’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Linden Thomas Advisory Services’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19,635
Closed -$8.25K – 550
2025
Q4 		$8.25K Buy
19,635
+186
+1% +$99 ﹤0.01% 485
2025
Q3 		$13.1K Buy
19,449
+704
+4% +$380 ﹤0.01% 483
2025
Q2 		$10.1K Buy
18,745
+1,138
+6% +$676 ﹤0.01% 478
2025
Q1 		$11.5K Buy
17,607
+1,324
+8% +$1.4K ﹤0.01% 460
2024
Q4 		$16.6K Buy
16,283
+2,914
+22% +$5.33K ﹤0.01% 469
2024
Q3 		$11.6K Buy
+13,369
New +$9.79K ﹤0.01% 465

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Linden Thomas Advisory Services's SGMO Position: Q1 2026 in Review

Linden Thomas Advisory Services sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2026, closing a stake of 19,635 shares — an estimated $8.25K sold.

Linden Thomas Advisory Services first reported a position in SGMO in Q3 2024 and held it in 6 quarters. The position peaked at $16.6K in Q4 2024. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • Linden Thomas Advisory Services reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2026 after selling out during the quarter.
  • Linden Thomas Advisory Services sold 19,635 SANGAMO THERAPEUTICS INC shares in Q1 2026, an estimated $8.25K.
  • Linden Thomas Advisory Services first reported a position in SANGAMO THERAPEUTICS INC in Q3 2024 and held it in 6 quarters.
  • Linden Thomas Advisory Services's SANGAMO THERAPEUTICS INC position peaked at $16.6K in Q4 2024.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Linden Thomas Advisory Services's 13F filing for Q1 2026, filed 10 Apr 2026.